Péter Pál Böjti on CREST-2 Trial: Does Carotid Revascularisation Still Matter?
Péter Pál Böjti, Neurointerventionist at Semmelweis University Department of Neurosurgery and Neurointervention, shared on LinkedIn:
”When absolute stroke risks are already low with modern pharmacotherapy, does carotid revascularisation still matter?
CREST‑2 suggests yes—in the right hands, for the right patients.
CREST‑2 is a strong reminder that even in the era of intensive, guideline‑driven pharmacotherapy, carotid revascularisation still has meaningful added value for selected asymptomatic patients.
In >2,400 patients with ≥70% asymptomatic carotid stenosis on optimised modern medical therapy, adding carotid stenting almost halved the 4‑year risk of stroke/death vs. medical therapy alone (≈6.0% → 2.8%), with a number needed to treat of ~31 to prevent one primary outcome event over 4 years.
At the same time, absolute stroke risks were low in all arms, underlining how far intensive risk‑factor control and lifestyle management have already brought us.
In the endarterectomy trial, intensive medical therapy alone performed so well that CEA did not reach a statistically significant additional benefit: 4‑year primary‑outcome rates were ≈5.3% with medical therapy vs. ≈3.7% with CEA, with a small absolute difference and overlapping confidence intervals.
Key practical points:
– Revascularisation provides significant additional clinical benefit on top of advanced pharmacological treatment in carefully selected asymptomatic patients.
– The clearest incremental benefit in CREST‑2 was seen with stenting plus best medical therapy, while CEA showed only a modest, statistically non‑significant numerical advantage over medical therapy alone.
– All of this was achieved in expert, high‑volume centres with rigorously credentialed operators and very low peri‑procedural complication rates.
So if we talk about “revascularisation vs. no revascularisation”, CREST‑2 is really saying:
‘Yes—but with the right patient, the right operator, and the right centre.”’

Stay updated with Hemostasis Today.
-
Nov 6, 2026, 22:54Vincenzo De Angelis: Presenting Trends and Challenges in Blood and Plasma Collection and Use in Europe
-
Nov 6, 2026, 22:50Alexis Caulier: Leveraging Epigenetic Silencing in HSCs to Modulate Platelet Aggregation
-
Nov 6, 2026, 22:40Panama Achieves Self-Sufficiency in Haemophilia Care – Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
-
Nov 6, 2026, 22:31Luisa Weiss: Exploring the Role of Platelets and Extracellular Vesicles in Calcific Aortic Valve Disease
-
Nov 6, 2026, 22:29Nour Al-Mozain: The Role of Therapeutic Apheresis and Cell Therapy in Advancing Regional Practice
-
Nov 6, 2026, 22:28Moazzam Shahzad: Celebrating Mentees Receiving the 2026 ASH Abstract Achievement Award
-
Nov 6, 2026, 22:25Habib Bennaceur: Self-Sufficiency in Haemophilia Care – A Major Achievement for Panama
-
Nov 6, 2026, 22:25Alessandro Lucchesi: Engineering Disease Trajectories in Myeloproliferative Neoplasms at RiseMPN 2026
-
Nov 6, 2026, 22:24Davood Bava: A New Practical Handbook for Advances in Transfusion Medicine